Actively Recruiting
Beijing Protocol in Patients Receiving More Than 5/10 HLA-mismatched Allo-HSCT
Led by Peking University People's Hospital · Updated on 2023-06-27
20
Participants Needed
1
Research Sites
156 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The aim of the study is to evaluate the efficacy and safety of Beijing protocol in malignant haematologic disease patients receiving more than 5/10 HLA-mismatched allo-HSCT.
CONDITIONS
Official Title
Beijing Protocol in Patients Receiving More Than 5/10 HLA-mismatched Allo-HSCT
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Hematologic malignancy patients
- Eligible for allogeneic hematopoietic stem cell transplantation
- No available HLA matched donor or related haploidentical donor
- Voluntary participation with signed informed consent form
You will not qualify if you...
- Severe infections
- Pregnant or lactating women
- Not eligible for hematopoietic stem cell transplantation
- Enrolled in another clinical trial within 1 month
- Unable to complete the study or considered unsuitable by investigator
- Unable or unwilling to understand or accept the informed consent form
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Deparment of Hematology, Peking University People's Hospital
Beijing, Beijing Municipality, China, 100044
Actively Recruiting
Research Team
Y
Yu Wang, Prof.
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here